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Abstract 
Bone metastases in advanced cancer frequently cause painful complications that impair patient 
physical activity and negatively affect quality of life.  Pain is often underreported and poorly 
managed in these patients.  The most commonly used pain assessment instruments are visual 
analogue scales, a single-item measure, and the Brief Pain Inventory questionnaire-short form.  
The World Health Organization analgesic ladder and the Analgesic Quantification Algorithm are 
used to evaluate analgesic use.  Bone-targeting agents, such as denosumab or 
bisphosphonates, prevent skeletal complications (ie, radiation to bone, pathologic fractures, 
surgery to bone, and spinal cord compression) and can also improve pain outcomes in patients 
with metastatic bone disease.  We have reviewed pain outcomes and analgesic use and 
reported pain data from an integrated analysis of randomized controlled studies of denosumab 
versus the bisphosphonate zoledronic acid (ZA) in patients with bone metastases from 
advanced solid tumors.  Intravenous bisphosphonates improved pain outcomes in patients with 
bone metastases from solid tumors.  Compared with ZA, denosumab further prevented pain 
worsening and delayed the need for treatment with strong opioids.  In patients with no or mild 
pain at baseline, denosumab reduced the risk of increasing pain severity and delayed pain 
worsening along with the time to increased pain interference compared with ZA, suggesting that 
use of denosumab (with appropriate calcium and vitamin D supplementation) before patients 
develop bone pain may improve outcomes.  These data also support the use of validated pain 
assessments to optimize treatment and reduce the burden of pain associated with metastatic 
bone disease. 
Word count: 246 (limit, 250) 
Key Words: pain, bone metastases, cancer, bone-targeting agents, denosumab, zoledronic 
acid, bisphosphonates, radiotherapy, analgesia, quality of life  
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Introduction 
Bone metastases are common in patients with advanced cancer, arising in 70% to 80% of 
patients with breast or prostate cancer and 30% to 40% of patients with lung cancer or other 
solid tumors [1].  Skeletal-related events (SREs), such as radiation to bone, pathologic 
fractures, surgery to bone, and spinal cord compression, are frequent pain-producing 
complications associated with bone metastases, and can impair physical activity and mobility, 
reduce social activity and ability to carry out daily tasks, decrease independence, and lower 
quality of life [1-5].  Furthermore, depression and anxiety are increased following SREs [6].  
Without systematic monitoring of pain using validated patient-reported outcome assessments, 
patients’ pain is often underreported and inadequately managed [7].  Indeed, undertreatment of 
bone pain is common, in up to 55% of patients with advanced cancer, which further adds to the 
burden of disease [8,9]. 
The World Health Organization (WHO) ladder, issued in 1996, is a 3-step framework for the 
management of cancer-related pain, in which the choice of drugs used to manage pain on the 
so-called analgesic ladder is determined by pain severity [10].  More recently, several 
organizations have issued comprehensive guidelines for management of cancer pain, 
encompassing topics such as pain assessment; treatment of mild, moderate to severe, and 
breakthrough pain; opioid switching, scheduling and titration of opioid analgesics; and 
management of adverse events (AEs) associated with opioids [11-13].  In addition to 
analgesics, these guidelines also emphasize the important role of bone-targeting therapy and 
radiotherapy in the management of bone pain due to bone metastases (Figure) [11,14]. 
Bone-targeting agents such as bisphosphonates and denosumab have been shown to reduce 
skeletal complications and the worsening of pain associated with bone metastases in patients 
with advanced solid tumors [15-23] and are recommended for patients with or without pain due 
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to bone metastases from solid tumors [11].  These different bone-targeting agents vary in their 
efficacy for prevention of SREs and pain.  There are also advantages and disadvantages with 
specific bone-targeting agents based on their different modes of action, routes of administration 
(ie, oral, intravenous, or subcutaneous), and toxicity profile that can contribute to the overall 
burden of disease [24]. 
The objective of this article is to provide an overview of pain data reported in clinical trials of 
bone-targeting agents in patients with advanced cancer and bone metastases.  In addition, we 
present new results on pain outcomes from an integrated analysis of patients who received 
either the nitrogen-containing bisphosphonate zoledronic acid (ZA) or denosumab, a fully 
human monoclonal antibody that inhibits RANKL, for prevention of SREs in breast cancer, 
prostate cancer, and other solid tumors. 
Pain and Analgesic Use Assessments in the Clinical Trial Setting 
Pain Assessments 
Effective pain assessment, preferably using at least two different items to evaluate the clinical 
importance of pain worsening or improvement [25], is a critical component for proper 
management of patients with bone metastases.  A variety of strategies discussed in this review 
have been used in clinical trials to assess pain in patients with cancer (Table 1).  A systematic 
review identified 49 studies that included patient-reported pain outcomes to assess 
bisphosphonate therapy in patients with bone metastases.  The most frequent approaches to 
assess pain, used in 24 of the publications, were single-item instruments such as visual 
analogue scale (VAS), numeric rating scale, and verbal rating scale [26].  These instruments 
have the advantage of being simple and quick to administer.  However, a single-item measure 
does not provide a full picture of a patient’s pain experience.  The most frequently used 
standardized instrument identified in the systematic review was the Brief Pain Inventory (BPI) 
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questionnaire, which was used, at least in part, in 13 studies.  It was also the only multi-item 
scale instrument used in more than a single study.  The BPI is a modified version of the 
Wisconsin Brief Pain Questionnaire that measures both pain and its functional impact, It was 
developed for patients with cancer and includes questions regarding pain location; pain relief; 
functional interference due to pain; and worst, least, and average severity on a 10-point scale. 
Several measures have been derived from the BPI short form (BPI-SF) results to provide a 
clearer picture of patient improvement or deterioration trends.  A key component of these 
measures is that a 2-point change on the BPI scale can be regarded as a minimally important 
difference when considering a change in a patient’s pain experience [27].  The minimally 
important difference was established based on both anchor- and distribution-based methods.  
Patients have been measured for pain improvement (≥2-point decrease) or worsening (≥2-point 
increase); progression from no or mild pain (score of ≤4) at baseline to moderate or severe pain 
(score >4); and pain interference, which can be further broken down into interference with 
normal daily activity, affect (ie, interpersonal relationships, enjoyment of life, and mood), and 
overall pain interference [28-30].  These measures can be calculated based on either time to 
change or the proportion of patients who experience a change.  Pain progression has also been 
defined as an increase of ≥30% in mean or worst pain intensity scores from baseline, but these 
criteria may be less clinically relevant than the 2-point minimum change in study populations 
with no or minimal pain at baseline [31].  
Analgesic Use Assessments 
In studies in which pain is assessed, concurrent analgesic use is an important consideration, 
although consistent use of these measures in clinical trials may be problematic.  Conventionally, 
this measurement has been divided into three broad categories based on the WHO analgesic 
ladder [10], which can be used as a surrogate measure of pain severity.  The Analgesic 
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Quantification Algorithm (AQA) is an expanded version of the WHO ladder that is divided into 
eight points: no analgesic, nonopioid analgesics, weak opioids, and strong opioids (≤75 mg, 
>75−150 mg, >150−300 mg, >300−600 mg, and >600 mg oral morphine equivalents per day) 
[32].  Unlike the stratification in the WHO ladder, which has a ceiling effect and tends to cluster 
patients at the strong opioid step, the stratification of strong opioids into five levels in the AQA 
allows for a greater ability to observe patient progression in analgesic use [32].  Results from 
the AQA can be used to observe trends in analgesic use, both in the proportion of patients who 
change analgesic use and in the time to change [28]. 
Pain Outcomes in Clinical Studies of Bisphosphonates in Patients With 
Bone Metastases From Solid Tumors 
The effects of bisphosphonates, such pamidronate, clodronate, and ibandronate, on pain 
outcomes in patients with bone metastases from advanced cancer were investigated before the 
development of denosumab.  In a randomized double-blind study enrolling patients with bone 
metastases from breast cancer (N=380), treatment with intravenous pamidronate was 
associated with less increased pain overall (P=0.046) and less increased pain in patients with 
pain at baseline (P=0.03) compared with placebo [33].  These improvements were maintained 
for 2 years in an extension study [34].  Among patients with no or mild pain at baseline, 
treatment with pamidronate decreased the incidence of ≥1-point pain increase (28% vs 37%) 
and delayed the time to increased pain (P=0.043) compared with placebo; similar results were 
observed among patients with baseline pain [34].  Increased analgesic use was also less 
frequent among patients who received pamidronate compared with placebo (26% vs 40%; 
P=0.011).  In a 2-year phase 1/2 trial assessing intravenous pamidronate among patients with 
bone metastases who were also receiving hormone therapy for breast cancer, treatment with 
pamidronate improved pain scores during the first year of treatment (P=0.002 at cycle 12) and 
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reduced analgesic use compared with placebo [35].  In a phase 3 study assessing intravenous 
ibandronate in patients with bone metastases from breast cancer (N=466), treatment with 
ibandronate improved patient quality of life and bone pain over time and decreased the need for 
analgesic use compared with placebo [36,37].  In two double-blind studies, treatment with oral 
ibandronate 50 mg once daily for up to 96 weeks in 564 patients with metastatic bone disease 
from breast cancer significantly reduced pain scores from baseline, reduced analgesic use, and 
resulted in fewer patients with moderate to intolerable pain compared with placebo [38].  A small 
open-label study in 13 patients with breast cancer reported decreased bone pain and analgesic 
use at 2 weeks following a loading dose of intravenous ibandronate (6 mg/d for 3 consecutive 
days) [39].  In a randomized double-blind study (N=209), treatment with clodronate did not 
increase the rate of palliative pain response versus mitoxantrone in patients with bone 
metastases and hormone-refractory prostate cancer [40]. 
More recently, the bisphosphonate ZA has been shown to improve pain and quality of life in 
patients with bone metastases from solid tumors, including breast, prostate, and lung cancers 
[19,20,22,41].  In a placebo-controlled phase 3 study assessing the efficacy and safety of ZA in 
men with bone metastases from hormone-refractory prostate cancer, the increase in mean pain 
score from baseline per the BPI at study month 15 was smaller in patients treated with ZA 
compared with placebo (0. 58 vs 0.88; P=0.134) [19].  No significant difference in analgesic use 
between treatment groups was reported [19].  Using a longitudinal approach to assess the 
proportions of patients with pain relief (≥2 points per the BPI) at various time points, Weinfurt et 
al reported that in the 138 patients (ZA, n=76; placebo, n=62) who completed the 60-week BPI 
assessment, treatment with ZA improved pain responses at all time points compared with 
placebo (overall mean rate, 33% vs 25%; P=0.036) [42].  A phase 3b open-label crossover 
study demonstrated that in patients with bone metastases from breast cancer, treatment with ZA 
reduced worst pain (P=0.008) and interference with activity (P=0.012), walking ability (P<0.001), 
Pain Outcomes in Bone Metastases 
October 22, 2014 
Patrick et al 8 
 
enjoyment of life (P=0.005), and sleep (P=0.015) relative to baseline [43].  Similarly, in a phase 
3 head-to-head trial to assess the efficacy and safety of ZA versus pamidronate in patients with 
bone metastases from breast cancer or multiple myeloma and osteolytic bone lesions, the BPI 
composite pain scores were reduced equivalently in the ZA and pamidronate treatment arms 
[44]. 
In an open-label study (N=312), among 237 patients with recent bone metastases from breast 
cancer evaluated for pain, 138 (58%) experienced a decrease from baseline in the BPI 
composite pain score at the end of treatment, and among 157 patients using analgesics at 
baseline, 83% reported decreased use or no change in use following treatment with ZA [45].  An 
open-label multicenter study investigating the effect of ZA on bone pain and analgesic treatment 
for 1 year in 604 patients with bone metastases from predominantly breast, urogenital, and lung 
tumors showed that pain assessed using the mean VAS decreased from baseline during the 
course of the study from 37.1 to 23.2 mm (P<0.0001) [46].  Treatment with ZA also decreased 
the need for analgesics per the mean VAS score (P<0.0001); 24% of patients with a baseline 
analgesic score of 4 no longer required the use of opioids at the end of the study [46]. 
Pain Outcomes in Clinical Studies Comparing Zoledronic Acid With 
Denosumab in Patients With Bone Metastases From Solid Tumors 
The approval of denosumab, a fully human monoclonal antibody, as a bone-targeting therapy 
for the prevention of SREs was based on the results of three randomized, double-blind, phase 3 
studies that enrolled 5723 patients with bone metastases from breast cancer, prostate cancer, 
or advanced solid tumors (excluding breast or prostate) or multiple myeloma [15-17].  Analyses 
of these studies have shown improvements in patient-reported pain outcomes associated with 
subcutaneous denosumab 120 mg compared with intravenous ZA 4 mg monthly (Table 2).  
Among patients with bone metastases from breast cancer in a randomized, double-blind study, 
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treatment with denosumab (n=1026) was associated with a lower incidence of pain worsening 
by ≥2 points per BPI-SF, delayed progression from no or mild pain to moderate or severe pain 
(9.7 vs 5.8 months; P=0.0024), improved pain interference, and delayed time to increased pain 
interference by ≥2 points (16.0 vs 14.9 months; P=0.09) compared with ZA (n=1020) [28].  Data 
from this study also showed that, independent of baseline pain levels, 10% more patients who 
received denosumab than ZA experienced improvement in health-related quality of life [47].  
Similarly, data from a randomized, double-blind trial in patients with bone metastases from 
castration-resistant prostate cancer who received denosumab (n=950) or ZA (n=951) [15], fewer 
patients treated with denosumab reported pain worsening, progression from no or mild pain to 
moderate or severe pain, pain interference, or the need for strong opioids per the AQA [29,30].  
Likewise, data from a randomized, double-blind study in patients with bone metastases from 
other solid tumors [17] showed that treatment with denosumab (n=800) versus ZA (n=797) 
delayed time to development of moderate or severe pain (4.7 vs 3.7 months; P=0.05), delayed 
pain worsening (5.6 vs 4.6 months; P=0.016) and worsening of pain interference (8.2 vs 4.8 
months; P=0.021), and reduced the need for strong opioids [48].  Because the study designs of 
the double-blind phase 3 studies were identical, an integrated analysis of pain outcomes per 
BPI and analgesic use per the AQA could be performed [49].  Overall, treatment with 
denosumab compared with ZA was associated with an 8% lower risk of increased pain severity 
(P=0.020) and reduced use of strong opioids (−13.4% difference).  Among patients with no or 
mild pain at baseline, denosumab delayed the increase in worst pain (4.6 vs 3.1 months), 
reduced the risk of increased severity by 13% (P=0.002), delayed the onset of moderate to 
severe pain (6.5 vs 4.7 months), and reduced the risk of progression to severe pain by 17% 
(P<0.001) compared with ZA.  Treatment with denosumab also delayed a ≥2-point increase in 
pain interference overall (11.1 vs 9.3 months; P=0.010), as well as pain interference with affect 
(8.4 vs 7.5 months; P=0.027) and with activity (8.3 vs 7.4 months; P=0.017) compared with ZA.  
In patients with no or mild pain at baseline, denosumab delayed the time to increase in pain 
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interference overall (10.3 vs 7.7 months; P<0.001), as well as pain interference with affect (9.2 
vs 7.4 months; P=0.003) and with activity (7.6 vs 6.0 months; P=0.002). 
New results from the integrated analysis of pain outcomes with denosumab versus ZA in phase 
3 trials are presented in Table 3.  Across all three studies, baseline BPI-SF pain scores (worst 
pain and pain interference, including pain interference subsets of activity and affect) were 
significantly higher in patients who had a history of SREs (P<0.0001 for all) and tended to be 
higher for patients who had elevated baseline bone turnover markers urinary N-telopeptide or 
baseline bone-specific alkaline phosphatase.  Among all patients with available patient-reported 
outcome data, treatment with either denosumab or ZA was associated with improvement in pain 
outcomes.  There was no difference between denosumab and ZA in the time to decrease in 
worst pain severity (2.8 months) or risk (HR, 1.01; P=0.881).  Denosumab did delay the time to 
increase in pain interference overall (11.1 vs 9.3 months; HR, 0.89; P=0.005), as well as pain 
interference with affect (8.4 vs 7.5 months; HR, 0.91; P=0.011) and with activity (8.3 vs 7.4 
months; HR, 0.90; P=0.009) compared with ZA.  Overall, fewer patients who received 
denosumab shifted to using a strong opioid (AQA score ≥3) compared with ZA (7.7% vs 9.1%).  
Additionally, treatment with denosumab compared with ZA delayed the time to and reduced the 
risk of moderate or severe pain (>4 points per the BPI-SF) in patients with prior SRE (5.7 vs 3.9 
months; HR, 0.81; P=0.019) and without prior SRE (6.7 vs 4.8 months; HR, 0.84; P=0.002). 
Pain Outcomes Reported in Clinical Studies of Radiotherapy in 
Combination With Bone-Targeting Agents 
Palliative radiotherapy, typically delivered as localized external-beam radiotherapy, is known to 
be effective for the management of pain associated with bone metastases [50].  Retrospective 
analysis of clinical trials has demonstrated improvement in pain with external-beam radiotherapy 
administered as a single fraction and as a longer course [51].  Longer courses of external-beam 
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radiotherapy are associated with fewer repeat treatments to the same site, while a single 
fraction offers greater convenience [50]. 
Combining radiotherapy with bone-targeting agents may have additive effects to provide acute 
pain relief [52].  In addition, concomitant treatment with radiotherapy and bone-targeting agents 
should have a favorable toxicity profile because of the general lack of overlapping toxicities [52].  
Results from a number of studies suggest that concurrent administration of bisphosphonates 
with external-beam radiotherapy at varying doses palliates bone pain [50].  Low-dose 
radiotherapy may also be a viable alternative to high-dose radiotherapy in patients receiving 
concomitant bisphosphonate therapy.  For example, ZA 4 mg monthly combined with low-dose 
radiotherapy regimens showed similar pain relief results (analgesic use and VAS pain scores) to 
ZA combined with high-dose radiotherapy in patients with breast cancer (N=100) [53].  Another 
study in patients with solid tumors (N=139; mostly lung, prostate, and breast cancer) in which 
patients were randomized to receive radiotherapy (single doses, 8 Gy vs 6 Gy; all patients 
received ZA) also supports the combined use of ZA with radiotherapy in terms of pain control, 
with both radiotherapy doses being equally effective for controlling pain [54].  Two small 
retrospective studies (N=23 and N=27 patients) in patients receiving background radiotherapy 
for bone metastases from renal cell carcinoma reported prolonged SRE-free survival among 
patients who received ZA 4 mg monthly combined with radiotherapy relative to radiotherapy 
alone [55,56].  Furthermore, in one of these retrospective studies, increased median duration of 
pain response was reported among patients who received ZA combined with radiotherapy 
compared with radiotherapy alone (25 vs 8.7 months; P=0.047) [55].  A phase 3 study in 470 
patients with metastatic prostate cancer indicated that a single dose of local radiotherapy 
provided pain relief (combination of WHO pain ladder score and analgesic use) similar to a 
single dose of intravenous ibandronate [57].  In two small observational studies (N=70 and 
N=45), ibandronate combined with external-beam radiotherapy in patients with bone 
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metastases from solid tumors significantly decreased opioid use (P<0.001 in both studies) and 
improved pain scores relative to baseline [58,59].  However, despite these preliminary results, 
prospective randomized studies are needed to determine whether the combination of a bone-
targeting agent with radiotherapy is more effective for pain relief than radiotherapy alone. 
Radionuclides with bone-seeking properties that localize to active sites of bone reaction and 
remodeling are also used to provide palliation to multiple sites of bone metastases from solid 
tumors [60].  Meta-analysis data for complete and complete/partial pain relief have shown a 
significant improvement for patients with solid tumors (predominantly prostate and breast 
cancer) who received radionuclides for pain control versus those who received placebo [50,61].  
There are limited data with bone-targeting agents in combination with radionuclides.  In a small, 
single-arm study, combining ZA with Sm-EDTMP-153 was safe and did not affect bone uptake 
of Sm-EDTMP-153 in 20 patients with metastatic prostate cancer [62].  A small retrospective 
nonrandomized study reported that ZA combined with strontium-89 was more effective at 
reducing discomfort and pain at specific sites (12 body regions) by VAS than either treatment 
alone in 49 patients with breast or prostate cancer and painful bone metastases [63].  In an 
interim analysis of 809 patients from a phase 3 randomized placebo-controlled study in patients 
with prostate cancer and bone metastases (41% of patients were using concurrent 
bisphosphonates), the times to initial opioid use and to external-beam radiation therapy use 
were lower in the radium-223 group than in the placebo group [64].  In addition, there was a 
survival benefit in the radium-223 group [65].  Moreover, patients receiving concurrent 
bisphosphonate treatment at study entry tended to have a longer time to first SRE than patients 
not receiving bisphosphonates [66].   
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Discussion 
Given that pain associated with bone metastases is often undertreated and that analgesics 
reduce the symptoms of bone pain but do not address the underlying cause, bone-targeting 
agents play an important role in delaying pain progression and reduce analgesic use by 
reducing the risk of potentially painful SREs such as fractures and spinal cord compression.  
Intravenous bisphosphonates such as ZA were previously the standard treatment option for 
bone metastases in patients with metastatic cancer, although more recently, subcutaneous 
denosumab has become an alternative and more efficacious option [12,67-70].  Patients 
receiving potent antiresorptive agents, including denosumab, should be properly supplemented 
with calcium and vitamin D to minimize the occurrence of hypocalcemia.  Both bisphosphonates 
and denosumab have been shown to reduce SREs thereby improving pain outcomes and 
reduce the need for strong opioids in patients with bone metastases from advanced solid tumors 
such as breast or prostate cancer [19,28-30,42,44-46,48,49,71].  In an integrated analysis of 
randomized double-blind studies of denosumab versus ZA in patients with bone metastases 
from advanced solid tumors reported here and previously [49], treatment with denosumab was 
associated with an overall reduced risk of increased pain severity and a delayed shift to the use 
of strong opioids compared with ZA [49].  Among patients with no or mild pain at baseline, 
denosumab delayed development of worst pain, reduced the risk of increased pain severity, and 
delayed time to pain increased pain interference per the BPI-SF versus ZA.  In this study, we 
found that the delay in time to progression to and the reduced risk of moderate to severe pain 
by denosumab versus ZA occurred independently of whether patients had prior SREs. 
Initial data from small studies suggest that combining the bisphosphonate ZA with either 
localized external-beam radiotherapy [55] or radionuclides (strontium-89) [63] provides a greater 
reduction in pain and discomfort relative to radiotherapy alone in patients with bone metastases.  
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A recent study on radium-223 used in combination with intravenous bisphosphonates in 
metastatic prostate cancer showed improvements in a number of pain measures per the BPI-SF 
[65].  Earlier initiation of analgesics and bone-targeting agents may prove beneficial in reducing 
rates of radiotherapy retreatment [72].  
There are several important considerations when assessing bone-targeting agents such as 
denosumab for the prevention of SREs in patients with bone metastases from advanced solid 
tumors.  Because bone metastases may remain asymptomatic (ie, without pain) for extended 
periods of time before damage to bone is detected, early treatment is essential.  An exploratory 
analysis of two randomized trials of ZA in patients with bone metastases from breast, lung, or 
solid tumors showed that those who had not yet developed bone pain at baseline had greater 
benefit from ZA in delaying time to SREs [73].  Furthermore, when interpreting the results of 
trials assessing bone-targeting agents in patients with bone metastases, it is important to 
consider the consequences of whether differing endpoints (ie, symptomatic vs skeletal survey) 
have been used.  Because SREs such as pathologic fractures may remain asymptomatic for 
extended time periods, the events may go unreported by a symptomatic scale, thereby affecting 
trial duration and the ability to capture treatment differentiation in pain.  Most recent studies of 
bone-targeting agents have assessed the effect of treatment on the risk or timing of ≥2-point 
increases in pain per the BPI-SF, whereas older studies have assessed differences between 
groups based on the VAS.  Regarding pain and SREs, exploratory results from phase 3 studies 
of the anticancer agents enzalutamide and abiraterone in patients with bone metastases and 
prostate cancer demonstrated the benefit of adding bisphosphonates to the therapeutic agent 
[74-76].  Additionally, differences in patient groups, such as the extent of metastasis at baseline, 
elevated bone turnover markers, and prior SREs, may affect pain and the response to therapy. 
Reducing the burden of pain associated with bone metastases is an important therapeutic goal 
in patients with advanced cancer.  There are a number of viable measures (eg, BPI-SF and 
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AQA) available to assist clinicians with the initial assessment of pain and to monitor the effect of 
treatment over time, and therefore, proper pain assessment in these patients should not be an 
obstacle to optimal pain management.  Bone-targeting agents such as bisphosphonates and 
denosumab have been shown to delay the progression of pain associated with bone 
metastases in patients with advanced cancer.  There are also data to suggest that earlier use of 
these agents in this setting (before patients develop bone pain) may improve pain outcomes, 
although the optimum timing and duration of bone-targeting treatment may warrant further 
investigation [73].  Nonetheless, the data presented in this review underscore the importance of 
using validated pain assessments to optimize treatment and reduce the burden of pain 
associated with bone metastases in advanced cancer.  
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Table 1. Pain and Analgesic Use Assessments in the Clinical Trial Setting 
Pain Assessment Tool Description of Tool Measures Derived From the Main Tool 
WHO Pain Ladder [10] 4-point scale:  
10. No analgesic 
21. Nonopioid 
32. Weak opioid 
43. Strong opioid 
 
AQA [28,32] 8-point scale: 
0. No analgesic 
1. Nonopioid 
2. Weak opioid 
3. ≤75 mg OME per day 
4. >75–150 mg OME per day 
5. >150–300 mg OME per day 
6. >300–600 mg OME per day 
7. >600 mg OME per day 
Strong opioid use 
 Proportion of patients who progress to strong 
opioid use (category >2) 
 Proportion of patients using strong opioids, by 
dose 
 Change in analgesic use 
 Time to strong opioid use (category >4) 
 Proportion of patients who progress to strong 
opioid use 
BPI-SF [27,28,31,77] 15-point questionnaire on pain 
severity and pain interference (scale, 
0–10) 
 0: no pain 
 1–4: mild pain 
 5–6: moderate pain 
 7–10: severe pain 
 0: no interference 
 10: complete interference 
Parameters 
 Pain location(s) 
 Worst pain 
 Least pain 
 Average pain 
 Current pain 
 Pain treatments and medications 
 Relief of pain from treatments 
 Pain interference with 
– Activity 
– Mood 
– Interpersonal relationships 
– Sleep 
– Enjoyment of life 
 A 2-point change is the minimally important 
difference 
Change in pain severity 
 Time to ≥2-point change from baseline 
 Proportion of patients with ≥2-point change 
Delay in pain progression 
 Time to moderate to severe pain (score, >4) 
 Proportion of patients who progressed to 
moderate to severe pain 
Change in pain interference 
 Time to ≥2-point change from baseline 
Progression of mean pain intensity 
 Increase of ≥30% from baseline  
Progression of worst pain intensity 
 Increase of ≥30% from baseline  
Progression of pain interference with activity 
 Increase of ≥50% from baseline  
AQA=Analgesic Quantification Algorithm; BPI-SF=Brief Pain Inventory-Short Form; OME=oral morphine 
equivalent; WHO=World Health Organization. 
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Table 2. Summary of Pain Outcomes in Clinical Studies of Denosumab in Patients With Bone Metastases From Breast 
Cancer, Castration-Resistant Prostate Cancer, and Other Solid Tumors 
 Pain Worsening
a
 
Time to Pain 
Worsening
a
 
Change in Pain 
Interference 
Time to Pain 
Interference 
Worsening
b
 
Shift to Strong 
Opioid Use
c
 HRQoL
d
 
Breast cancer [28,47] 
(N=2046) 
All 
patients 
7% mean relative 
difference 
favoring 
denosumab vs 
ZA 
Denosumab:  
8.5 mo 
ZA: 7.4 mo 
 
HR, 0.90 
95% CI, 0.80–1.01 
P=0.08 
18% and 10% mean 
relative difference in 
pain interference with 
affect and activity, 
respectively, favoring 
denosumab vs ZA
e
 
Denosumab:  
16.0 mo 
ZA: 14.9 mo 
 
HR, 0.89 
95% CI, 0.78–1.02 
P=0.09 
20% relative 
difference 
favoring 
denosumab 
10% more 
patients improved 
and 7% fewer 
patients worsened 
with denosumab 
vs ZA 
No/mild 
pain at 
baseline 
15% mean 
relative difference 
favoring 
denosumab vs 
ZA 
Denosumab:  
9.7 mo 
ZA: 5.8 mo 
 
HR, 0.78 
95% CI, 0.67–0.92 
P=0.0024 
21% and 21% mean 
relative difference in 
pain interference with 
affect and activity, 
respectively, favoring 
denosumab vs ZA
e
 
Denosumab:  
15.2 mo 
ZA: 10.9 mo 
 
HR, 0.85 
95% CI, 0.71–1.01 
P=0.058 
4% relative 
difference 
favoring 
denosumab vs 
ZA
e
 
14% more 
patients improved 
with denosumab 
vs ZA 
Castration-resistant prostate cancer [29,30,78] 
(N=1901) 
All 
patients 
Trend favored 
denosumab over 
ZA 
Denosumab: 86 d 
ZA: 80 d 
 
HR, 0.93 
95% CI, 0.84–1.03 
P=0.168 
19% and 17% mean 
relative difference in 
pain interference with 
affect and activity, 
respectively, favoring 
denosumab vs ZA 
Denosumab: 8.3 mo 
ZA: 7.5 mo 
P=0.19 
8% relative 
difference 
favoring 
denosumab vs ZA 
The proportion of 
patients with 
improvement was 
generally similar 
or slightly higher 
with denosumab 
vs ZA
e
 
No/mild 
pain at 
baseline 
Trend favored 
denosumab over 
ZA 
Denosumab:  
177 d 
ZA: 148 d 
 
HR, 0.89 
95% CI, 0.77–1.04 
P=0.142 
38% and 41% mean 
relative difference in 
pain interference with 
affect and activity, 
respectively, favoring 
denosumab vs ZA 
Denosumab: 8.3 mo 
ZA: 6.6 mo 
 
HR, 0.83 
95% CI, 0.71–0.98 
P=0.023 
0.6% relative 
difference 
favoring ZA vs 
denosumab
e
 
≥5-point 
decreases in 
FACT-G total 
scores were 6.8% 
more frequent with 
ZA than 
denosumab 
Other solid tumors [18,48] 
(N=1597) 
All No difference Denosumab: 5.6 4% mean relative Denosumab: 8.2 mo 27% relative 4% more patients 
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patients between 
denosumab and 
ZA over the 
course of the 
study
e
 
mo 
ZA: 4.6 mo 
 
HR, 0.83; 95% CI, 
0.71–0.97 
P=0.016) 
difference in pain 
interference with affect 
favoring denosumab vs 
ZA; 3% mean relative 
difference in pain 
interference with 
activity favoring ZA vs 
denosumab
e
 
ZA: 7.5 mo 
 
HR, 0.89 
95% CI, 0.76–1.04 
P=0.153
e
 
difference 
favoring 
denosumab vs ZA 
had a <5-point 
decrease in 
FACT-G total 
scores with 
denosumab vs 
ZA
e
 
No/mild 
pain at 
baseline 
Trend favored 
denosumab over 
ZA
e
 
Denosumab:  
4.7 mo 
ZA: 3.7 mo 
 
HR, 0.81 
95% CI, 0.66–1.00 
P=0.050 
2% and 16% mean 
relative difference in 
pain interference with 
affect and activity, 
respectively, favoring 
denosumab vs ZA
e
 
Denosumab:  
8.2 mo 
ZA: 4.8 mo 
 
HR, 0.77 
95% CI, 0.61–0.96 
P=0.021 
33% relative 
difference 
favoring 
denosumab vs 
ZA
e
 
NR 
AQA=Analgesic Quantification Algorithm; FACT-G=Functional Assessment of Cancer Therapy-General questionnaire; HR=hazard ratio; 
HRQoL=health-related quality of life; NR=not reported; ZA=zoledronic acid. 
a
For all patients, ≥2-point increase; for patients with no/mild pain at baseline, >4-point increase. 
b
For all patients and for patients with no/mild pain at baseline, ≥2-point increase. 
c
Proportion of patients who switched from nonnarcotic and weak analgesics (AQA ≤2) to strong opioids. 
d
≥5-point improvement per FACT-G total score over course of study unless otherwise noted. 
e
Data not previously published. 
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Table 3. Changes in Pain Outcomes From Baseline in an Integrated Analysis of Denosumab Versus Zoledronic Acid in Patients With 
Bone Metastases From Breast Cancer, Castration-Resistant Prostate Cancer, and Other Solid Tumors Excluding Multiple Myeloma 
 Incidence, n/N (%)  Median Time, mo   
Parameter Denosumab 
Zoledronic 
Acid  Denosumab 
Zoledronic 
Acid Difference 
Hazard Ratio 
(95% CI) P Value 
Decrease in worst pain severity
a
 1326/2048 (65) 1320/2037 (65)  2.8 2.8 0 1.01 (0.93–1.09) 0.881 
Increase in pain interference
b
         
Overall 1227/2469 (50) 1283/2443 (53)  11.1 9.3 1.8 0.89 (0.83–0.97) 0.005 
Affect 1318/2418 (55) 1361/2402 (57)  8.4 7.5 0.9 0.91 (0.84–0.98) 0.011 
Activity 1260/2295 (55) 1299/2241 (58)  8.3 7.4 0.9 0.90 (0.83–0.97) 0.009 
Patients using strong opioids
c
   (7.7)  (9.1)  — — — — — 
Moderate to severe worst pain
d
         
Overall 853/1386 (62) 863/1297 (67)  6.5 4.7 1.8 0.83 (0.76–0.92) 0.0002 
 Prior skeletal-related event (yes) 265/429 (62) 247/366 (68)  5.7 3.9 1.8 0.81 (0.68–0.97) 0.019 
 Prior skeletal-related event (no) 588/957 (61) 616/931 (66)  6.7 4.8 1.9 0.84 (0.74–0.94) 0.002 
AQA=Analgesic Quantification Algorithm; BPI-SF=Brief Pain Inventory-Short Form; OME=oral morphine equivalent. 
a
Patients with a ≥2-point decrease from baseline in BPI-SF worst pain score. 
b
Patients with a ≥2-point increase from baseline in BPI-SF pain interference score. 
c
Mean proportion of patients with an AQA score ≥3 (strong opioids from ≤75–600 mg OME per day) averaged over study weeks 5–41.    
d
Patients with a >4-point BPI-SF worst pain score. 
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Figure Legend 
 
Figure.  Algorithm for the management of pain due to bone metastases. Reproduced with 
permission from Ripamonti CI, Santini D, Maranzano E, et al. Management of 
cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23(suppl 
7):vii139-54.  SRE=skeletal-related event. 
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